COSA 2021: Subgroup Analyses of JAVELIN Bladder 100 Support Avelumab as First-Line Maintenance for Advanced UC Without Disease Progression
Several subgroups were examined.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.